Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
9.44
Dollar change
-0.02
Percentage change
-0.21
%
Index- P/E- EPS (ttm)-1.59 Insider Own5.24% Shs Outstand61.92M Perf Week-3.58%
Market Cap584.71M Forward P/E- EPS next Y-1.71 Insider Trans1.20% Shs Float58.69M Perf Month-8.53%
Income-97.33M PEG- EPS next Q-0.44 Inst Own94.87% Short Float4.07% Perf Quarter39.85%
Sales2.81M P/S208.08 EPS this Y-9.83% Inst Trans23.91% Short Ratio3.40 Perf Half Y105.22%
Book/sh3.80 P/B2.49 EPS next Y2.22% ROA-40.19% Short Interest2.39M Perf Year209.51%
Cash/sh3.81 P/C2.48 EPS next 5Y14.30% ROE-44.84% 52W Range2.25 - 13.70 Perf YTD39.85%
Dividend Est.- P/FCF- EPS past 5Y1.09% ROI-39.92% 52W High-31.09% Beta2.28
Dividend TTM- Quick Ratio17.71 Sales past 5Y-1.10% Gross Margin22.50% 52W Low319.56% ATR (14)0.74
Dividend Ex-Date- Current Ratio17.71 EPS Y/Y TTM36.12% Oper. Margin-3945.24% RSI (14)44.06 Volatility7.25% 7.66%
Employees76 Debt/Eq0.05 Sales Y/Y TTM-55.77% Profit Margin-3470.05% Recom1.62 Target Price13.25
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q20.27% Payout- Rel Volume0.79 Prev Close9.46
Sales Surprise57.59% EPS Surprise6.04% Sales Q/Q27.15% EarningsFeb 27 BMO Avg Volume702.61K Price9.44
SMA20-10.69% SMA502.45% SMA20066.53% Trades Volume554,281 Change-0.21%
Date Action Analyst Rating Change Price Target Change
Mar-13-24Initiated RBC Capital Mkts Outperform $14
Sep-25-23Initiated Goldman Neutral $5
Aug-23-23Upgrade H.C. Wainwright Neutral → Buy $5 → $14
Aug-22-23Upgrade Stifel Hold → Buy $4 → $11
May-04-23Downgrade Goldman Buy → Neutral $9 → $3
Mar-10-23Downgrade H.C. Wainwright Buy → Neutral $20 → $6
Mar-10-23Downgrade Credit Suisse Outperform → Neutral $11 → $8
Mar-09-23Downgrade Stifel Buy → Hold $35 → $6
Feb-28-23Downgrade Morgan Stanley Overweight → Equal-Weight $27 → $8
Feb-24-23Downgrade BofA Securities Neutral → Underperform
Today 04:05PM
Mar-22-24 04:30PM
Mar-18-24 07:00AM
Mar-08-24 04:30PM
Mar-05-24 08:00AM
09:35AM Loading…
Feb-28-24 09:35AM
Feb-27-24 09:23PM
08:10AM
07:35AM
07:00AM
Feb-20-24 04:01PM
Feb-06-24 08:00AM
Dec-07-23 04:30PM
Nov-10-23 04:30PM
Nov-09-23 08:00AM
03:43PM Loading…
Nov-08-23 03:43PM
Nov-07-23 08:03AM
07:00AM
Oct-31-23 08:50AM
Sep-22-23 08:00AM
Sep-15-23 04:30PM
Sep-07-23 08:00AM
Aug-25-23 09:16AM
Aug-24-23 10:15AM
08:42AM
01:35AM
Aug-22-23 02:02PM
11:39AM
07:00AM
Aug-11-23 04:53PM
08:15AM Loading…
Aug-03-23 08:15AM
07:01AM
06:55AM
Jul-27-23 07:00AM
Jul-10-23 07:00AM
Jul-07-23 05:30PM
Jun-20-23 07:00AM
Jun-09-23 04:54PM
May-16-23 06:07AM
May-15-23 11:37PM
08:15AM
07:05AM
07:00AM
May-08-23 04:05PM
May-05-23 06:06PM
Apr-26-23 01:01PM
Apr-07-23 05:00PM
Apr-05-23 08:00AM
Mar-10-23 05:00PM
Mar-09-23 10:06PM
08:15AM
07:00AM
Mar-07-23 06:06AM
Mar-06-23 04:05PM
Feb-28-23 10:00AM
Feb-24-23 12:52PM
08:00AM
Feb-23-23 10:00AM
Feb-16-23 09:55AM
Feb-10-23 05:27PM
Feb-08-23 05:00PM
Feb-01-23 12:00PM
Jan-26-23 09:55AM
Jan-17-23 11:15PM
04:01PM
Jan-13-23 05:00PM
Jan-11-23 07:47AM
Jan-08-23 11:42AM
Jan-05-23 05:44AM
Jan-04-23 07:02AM
07:01AM
Dec-05-22 05:21PM
Dec-02-22 09:55AM
Dec-01-22 04:01PM
Nov-17-22 11:21AM
Nov-16-22 09:55AM
Nov-11-22 06:33PM
Nov-08-22 08:35AM
07:18AM
Nov-07-22 05:00PM
Nov-02-22 07:05AM
Nov-01-22 05:29PM
Oct-27-22 10:02AM
Oct-21-22 09:35AM
Oct-12-22 07:30AM
Oct-07-22 05:00PM
Sep-28-22 06:19AM
Sep-09-22 05:00PM
Sep-06-22 04:01PM
Aug-18-22 07:42AM
Aug-16-22 07:05AM
Aug-15-22 09:28PM
04:08PM
Aug-11-22 08:15AM
07:00AM
Aug-04-22 08:07AM
Aug-02-22 08:00AM
Jul-15-22 08:00AM
Jul-11-22 05:00PM
Jul-05-22 07:00AM
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tourangeau GregVice President, FinanceMar 08 '24Sale11.724,88457,21911,807Mar 08 06:05 PM
Sapir AlexSee RemarksMar 04 '24Buy11.3543,360492,02843,360Mar 05 04:15 PM
Tourangeau GregPrincipal Accounting OfficerMay 10 '23Sale3.3121069515,992May 11 04:12 PM